Allarity Therapeutics Inc (ALLR) Stock Price, Quote & News

Company Profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a...

Industry: Biotechnology

Sector: Healthcare

Phone: 401 426 4664

Website: www.allarity.com

Address:

123 E. Tarpon Ave., Tarpon Springs, United States

Dizzier47 Sep. 19 at 4:23 PM

$ALLR "stock market is smth smth patient people get the money of impatient ppl smth smth" - a guy with money

0 · Reply

Hlmx Sep. 18 at 6:03 PM

$ALLR This stock is frozen; it's not moving 😃

0 · Reply

Amscru80 Sep. 18 at 1:52 PM

$ALLR 🌋🌋

0 · Reply

rogerrabbit904 Sep. 18 at 1:08 PM

$ALLR Continuing to quietly gain strength for Stenoparib https://allarity.com/press-release/allarity-therapeutics-granted-japanese-patent-for-stenoparib-drp-companion-diagnostic-further-strengthening-stenoparib-development/

0 · Reply

Wody Sep. 17 at 8:05 PM

$ALLR 160k vol to move it .005! Woohoo!

0 · Reply

ka1954 Sep. 17 at 2:46 PM

$ALLR i am seeing so many stocks going up 50% - 300%+ everyday, i can't believe we are stuck this fucking turd allr

1 · Reply

RAKIN13 Sep. 17 at 12:16 PM

$IOVA I hope $ALLR will behave like this one day

1 · Reply

martyn78 Sep. 17 at 7:44 AM

Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $ALLR & $CLDI good status

0 · Reply

Kvakklunch Sep. 16 at 4:57 PM

$ALLR Trash Volume, will end red today as well.

0 · Reply

biotrade123 Sep. 16 at 4:37 PM

$ALLR isn't an update due or could be expected from the VA trail?

1 · Reply

Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

Sep 11, 2026, 8:00 AM EDT - 9 days ago

Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

Aug 14, 2026, 8:00 AM EDT - 5 weeks ago

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Jul 7, 2026, 8:00 AM EDT - 2 months ago

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Jun 30, 2026, 8:00 AM EDT - 2 months ago

Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic

2026-06-18T12:18:06.000Z - 3 months ago

Allarity to present trial-in-progress poster on Phase 2 stenoparib trial

Jun 18, 2026, 8:00 AM EDT - 3 months ago

Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026

May 15, 2026, 4:30 PM EDT - 4 months ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

May 8, 2026, 8:45 AM EDT - 4 months ago

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

May 5, 2026, 8:00 AM EDT - 4 months ago

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

2026-04-27T13:21:02.000Z - 4 months ago

Allarity receives notice of allowance from USPTO

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

2026-03-06T13:19:41.000Z - 6 months ago

Allarity closes $20M financing for stenoparib advancement

Mar 6, 2026, 8:00 AM EST - 6 months ago

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

2026-02-18T13:25:56.000Z - 7 months ago

Allarity doses first patients in Phase 2 trial of SCLC

Feb 18, 2026, 8:15 AM EST - 7 months ago

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

2026-02-03T13:20:33.000Z - 7 months ago

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

Feb 3, 2026, 8:00 AM EST - 7 months ago

Allarity Therapeutics announces that its collaborative Phase 2 trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment

2025-12-31T13:05:34.000Z - 8 months ago

Allarity CEO says 2026 represents an ‘inflection point’

Dec 31, 2025, 8:00 AM EST - 8 months ago

Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders

2025-12-03T14:15:27.000Z - 9 months ago

Allarity files $50M mixed securities shelf

2025-11-14T14:06:08.000Z - 10 months ago

Allarity reports Q3 EPS (19c) vs ($7.71) last year

Nov 14, 2025, 9:00 AM EST - 10 months ago

Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates

2025-09-25T21:25:29.000Z - 11 months ago

Allarity files to sell 1.56M shares of common stock for holders

2025-09-22T12:20:54.000Z - 12 months ago

Allarity presents new Phase 2 clinical data for Stenoparib

Sep 22, 2025, 8:00 AM EDT - 12 months ago

Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months

Sep 17, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025

2025-08-27T01:00:00.000Z - 1 year ago

Why Is Allarity Therapeutics Stock (ALLR) Up 95% Today?

2025-08-26T12:05:59.000Z - 1 year ago

Allarity announces FDA granted Fast Track designation to stenoparib

Aug 26, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer

Aug 15, 2025, 4:30 PM EDT - 1 year ago

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

2025-07-28T09:50:42.000Z - 1 year ago

Allarity initiated with a Buy at Ascendiant

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization

2025-07-07T12:26:02.000Z - 1 year ago

Allarity appoints Jeff Ervin as CFO

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer

2025-06-30T14:34:35.000Z - 1 year ago

Allarity gets Australian patent acceptance notice for DRP companion diagnostic

2025-06-27T12:10:38.000Z - 1 year ago

Allarity announces second patient dosed in Phase 2 trial of stenoparib

Jun 27, 2025, 8:00 AM EDT - 1 year ago

Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Jun 11, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Announces Changes to Board of Directors

2025-06-04T12:05:09.000Z - 1 year ago

Allarity announces research collaboration with IBRI

May 9, 2025, 4:05 PM EDT - 1 year ago

Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment

Mar 13, 2025, 8:30 AM EDT - 1 year ago

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Mar 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Feb 24, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Feb 6, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Jan 30, 2025, 8:00 AM EST - 1 year ago

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Nov 18, 2024, 8:00 AM EST - 1 year ago

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Dizzier47 Sep. 19 at 4:23 PM

$ALLR "stock market is smth smth patient people get the money of impatient ppl smth smth" - a guy with money

0 · Reply

Hlmx Sep. 18 at 6:03 PM

$ALLR This stock is frozen; it's not moving 😃

0 · Reply

Amscru80 Sep. 18 at 1:52 PM

$ALLR 🌋🌋

0 · Reply

rogerrabbit904 Sep. 18 at 1:08 PM

0 · Reply

Wody Sep. 17 at 8:05 PM

$ALLR 160k vol to move it .005! Woohoo!

0 · Reply

ka1954 Sep. 17 at 2:46 PM

$ALLR i am seeing so many stocks going up 50% - 300%+ everyday, i can't believe we are stuck this fucking turd allr

1 · Reply

RAKIN13 Sep. 17 at 12:16 PM

$IOVA I hope $ALLR will behave like this one day

1 · Reply

martyn78 Sep. 17 at 7:44 AM

0 · Reply

Kvakklunch Sep. 16 at 4:57 PM

$ALLR Trash Volume, will end red today as well.

0 · Reply

biotrade123 Sep. 16 at 4:37 PM

$ALLR isn't an update due or could be expected from the VA trail?

1 · Reply

biotrade123 Sep. 16 at 3:17 PM

$ALLR those who thought a trend reversal in progress at $1.40's now holding a bag?? :-(

1 · Reply

Kvakklunch Sep. 16 at 2:15 PM

$ALLR Just save your money and save your scraps. Boardmembers x 4 = none have bought. Company insiders buying = none! Phase 2 results, late summer 2026 = no! Instead you get trash news about patents and a fucking buyout project lol? Trend = below 1$. How many signs do u need?

0 · Reply

anachartanalyst Sep. 16 at 10:01 AM

$ALLR https://anachart.com/wp-content/uploads/2026/09/1789552872_soc-img.jpg

2 · Reply

CantAffordMe Sep. 15 at 6:25 PM

$ALLR I have serious doubts that stenoparib is proving to be efficacious in the trials. News always leaks and if results were positive we’d be trending up. All this BS with the SPAC and patents is just jensen posturing as if things were going well. he is a nice little criminal just like his parents.

1 · Reply

ka1954 Sep. 15 at 2:06 PM

$ALLR all microcap/nanocap stocks are dead recently. no stocks are going up and if they are, they are being sold heavily

0 · Reply

RAKIN13 Sep. 15 at 2:04 PM

$ALLR insane wtf is going on. When is the data readout??? Absolute joke.

0 · Reply

Popsiclestick Sep. 15 at 1:38 PM

$ALLR gonna see below a $1, unbelievable

1 · Reply

ka1954 Sep. 15 at 1:36 PM

$ALLR any other stock on this news would have gone up atleast 200%+ Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development

0 · Reply

Amscru80 Sep. 15 at 1:19 PM

$ALLR

0 · Reply

ganta7 Sep. 15 at 12:08 PM

$ALLR I guess some news new patent from Japan

1 · Reply

Wody Sep. 14 at 11:56 PM

$ALLR go!!!!!

0 · Reply

Wody Sep. 14 at 11:56 PM

$ALLR fucking…

0 · Reply

Market Cap	19.25M
Revenue (ttm)	320,000.00
Net Income (ttm)	-11.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,509.37%
Debt to Equity Ratio	0.21

Volume	186,500
Avg Vol	87,040
Day's Range	N/A - N/A
Shares Out	15.91M
Stochastic %K	42%
Beta	0.56
Analysts	Sell
Price Target	$11.00